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Background: Subjective quality of life (SQOL) is an established outcome measure in schizophrenia. In spite of
the substantial proportion of elderly in the total schizophrenia population, evaluation of their SQOL and its
determinants has been scarce and ﬁndings from epidemiological samples are lacking.
Methods: We assessed SQOL in elderly Dutch patients with schizophrenia or schizoaffective disorder (n = 107;
mean age 68 years), treatedwithin a psychiatric catchment area. Demographic, clinical and social variableswere
evaluated for their impact on SQOL.
Results: The mean SQOL score was 4.83, moderately surpassing the midpoint of the SQOL scale. Nearly half of all
patients (47.7%) reported an overall favorable SQOL. Of the total variance in SQOL, clinical variables explained
50%, and social variables explained 16%, while demographic factors did not contribute. In multivariable analysis,
less self-reported depressive symptoms, worse global neurocognition, and higher observer-based level of social
functioning signiﬁcantly predicted a higher SQOL, explaining 53% of the total variance.
Conclusion: The relatively high level of SQOL in this epidemiological sample of elderly patients is in line with what
has been reported for both older and younger schizophrenia populations. Depressive symptoms are a robust
predictor of SQOL in late life schizophrenia, clearly outweighing psychotic symptoms. Thisﬁnding hasmajor clinical
relevance, as depression is amenable to therapeutic intervention.© 2013 Elsevier B.V. All rights reserved.1. Introduction
Subjective quality of life (SQOL) is now an established outcome
measure in the care of persons with schizophrenia (Awad et al.,
2012). SQOL refers to a person's sense of well-being and satisfaction
with life. While aiming at a global perspective, it is generally seen as a
multidimensional concept involving various life domains. Although the
capacity for self-appraisal in individuals with psychotic disorders has
been questioned due to their lack of insight and cognitive restrictions,
it has been demonstrated that SQOL can be reported by schizophrenia
patients with a high degree of reliability and concurrent validity
(Voruganti et al, 1998).
Identifying the critical factors that inﬂuence SQOL in schizophrenia
has major clinical relevance, as it may help to design services and in-
terventions that can assist patients in leading more fulﬁlling lives.
Research of SQOL in schizophrenia has been hampered by disparities
in deﬁnitions andmeasurements. Still, a number of variables associated
with SQOL emerge from the existing literature. Psychiatric symptoms14, 1075 BH Amsterdam, The
77.
sters).
rights reserved.have consistently been found to relate negatively to SQOL, but they
explain only a modest proportion of variance. A recent meta-analysis
demonstrated that general psychopathology (e.g., depression, anxiety)
contributes stronger to SQOL than positive and negative psychotic
symptoms (Eack and Newhill, 2007). While neurocognition is largely
unrelated to SQOL (Tolman and Kurtz, 2012), social cognition contributes
to SQOL, with patients with a relatively unimpaired theory of mind
reporting a lower SQOL (Maat et al., 2012). Cross-sectional studies have
suggested that favorable social factors (e.g., independent living, more
social support) contribute to a higher SQOL (Yanos and Moos, 2007). In
the long-term, improvement in psychosocial factors appears to increase
SQOL (Ritsner et al., 2012). Furthermore, meeting unmet needs for care
(as reported by patients) may cause SQOL to improve (Slade et al, 2005).
In comparison, the number of studies dedicated to quality of life in
late life schizophrenia has been modest. This stands in contrast to the
substantial proportion of elderly in the total schizophrenia population
(Meesters et al., 2012), and the expected disproportionately rapid
growth of their numbers in the next decades (Cohen et al., 2008). A
number of studies assessed speciﬁc aspects of quality of life in older
schizophrenia patients, focussing for example on health-related function-
ing andwell-being (e.g. Mittal et al., 2006). A recent cross-sectional study
(Folsom et al., 2009) of middle-aged and older community-dwelling
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mental health quality of life, leaving open the possibility that quality of
life may actually improve with aging.
To the best of our knowledge, only one study measured SQOL
using a generic concept. Bankole et al. (2007) found a lower SQOL
in elderly schizophrenia patients in New York (n = 198; mean age
62 years), compared to age-matched peers. Notably, the mean SQOL
in the schizophrenia group was well above the threshold for a positive
level of satisfaction and the absolute differences between the two
groups were only modest. Of the 19 selected independent variables, in
regression analysis six were signiﬁcantly associated with a higher
SQOL: fewer depressive symptoms, more cognitive deﬁcits, fewer
acute life stressors, fewer medication side effects, lower ﬁnancial strain,
and better self-rated health. Overall, themodel explained 55% of variance
in SQOL. However, the generalizability of these ﬁndings is uncertain, as
the sample was restricted to community-living patients with early
onset schizophrenia.
To expand our knowledge on SQOL in late life schizophrenia, we
evaluated SQOL in an epidemiological representative sample of elderly
patients with schizophrenia or schizoaffective disorder, aiming to in-
clude all individuals that were in contact with mental health services
within a Dutch psychiatric catchment area. A number of demographic,
clinical and social variables identiﬁed in the literature were evaluated
for their impact on SQOL.We sought to answer the following questions:
(1) what is the level of SQOL and its variability among participants?, (2)
which variables predict SQOL and towhat extent do the predicting vari-
ables overlap in their effects on SQOL?, (3) what part of the variance in
SQOL is explained by the combined variables?
2. Method
2.1. Participants
Data were derived from an observational, cross-sectional study of
an epidemiological sample of older schizophrenia and schizoaffective
patients. Details of the study methods are provided elsewhere
(Meesters et al., 2011). Brieﬂy, between March 2006 and September
2008 we recruited 177 patients aged 60 years and over, within the
psychiatric catchment area of the southern district of Amsterdam.
A total of 107 patients were able and willing to provide written
informed consent for the present study (Fig. 1). Basic demographic
and clinical characteristics did not differ between consenting and
non-consenting patients, with the exception of female gender
(χ2 = 4.80; DF = 1; p = 0.03) and compulsory admissions
(χ2 = 7.01; DF = 1; p = 0.008), that were more frequent amongEligible for study inclusion (n  = 177)
Informed consent requested (n = 149)
Patients included in the study (n = 107)
Fig. 1. Flow diagramnon-consenting patients. In consenting patients diagnosis was
conﬁrmed through the Mini-International Neuropsychiatric Inter-
view Plus (MINI-Plus; Sheehan et al., 1998): 84 patients (78.5%)
were diagnosed with schizophrenia (DSM-IV-TR: 295.10, 295.20,
295.30, 295.60, 295.90; American Psychiatric Association, 2000), and
23 patients (21.5%) with schizoaffective disorder (DSM-IV-TR:
295.70). The study was approved by the Medical Ethics Committee of
the VU University Medical Center, Amsterdam, The Netherlands.
2.2. Instruments
We documented three predictor variable domains (demographic,
clinical, social), comprising 17 independent variables. Demographic
data were derived from medical records and conﬁrmed in the
face-to-face interviews. Age at onset was deﬁned as the earliest age at
which in retrospect DSM-IV-TR criteria for the disorder were fulﬁlled
(Meesters et al., 2012). Psychiatric symptomatology was assessed by
the Positive and Negative Syndrome Scale (PANSS; Kay et al., 1987),
the Center for Epidemiologic Studies Depression Scale (CES-D; Radloff,
1977) and the Beck Anxiety Inventory (BAI; Beck, 1990). The PANSS
consists of 30 items, rated by the interviewer on a scale from 1 (absent)
to 7 (extreme). Total PANSS scores may range from 30 to 210. The pos-
itive and the negative PANSS subscales both comprise 7 items (scoring
range 7 to 49). Symptomatic remission status was determined through
a low score on eight individual PANSS items (severity criterion of the
Remission in Schizophrenia Working Group; Andreasen et al., 2005),
with remitted participants in addition having had no psychiatric hospi-
talization in the previous six months (modiﬁed time criterion). The
CES-D is a 20-item self-report scale, measuring the presence and dura-
tion of depressive symptoms during the previous week. Summation
results in scores ranging from 0 to 60. The BAI is a 21-item self-report
scale, that evaluates presence and intensity of anxiety-related symptoms
during the previous week. Scores range from 0 to 63. Global cognitive
status was assessed through the Mini Mental State Examination
(MMSE; Folstein et al., 1975). In addition, the presence of ten chronic
physical disorders was evaluated (sum score 0–10).
To evaluate their social network, participants estimated the number
of persons outside of their household, with whom they had regular and
meaningful contact. Also, the number of persons (partner included, if
present) who they experienced as being emotionally or materially
supportive to them, was documented. Self-report of involvement in
ten social activities was measured through the Social Participation
Scale (Depla et al., 2003), with scores ranging from 0 (no activities) to
20 (regular participation in all activities). The Social and Occupational
Functioning Assessment Scale (SOFAS; American Psychiatric Association,Not able to provide consent (n = 28):
- severely disturbed behaviour (n = 9)
- strong denial of illness (n = 6)
- backed out of services (n = 6)
- language problem (n = 3)
- serious physical illness (n = 2)
- severe dementia (n = 1)
- intellectual disability (n = 1)
Refusing to provide consent (n = 42):
- at initial request (n = 35)
- withdrawal during study (n = 7)
of the study.
Table 1
Characteristics of the patient sample (n = 107).
Age: mean years (SD) 67.9 (7.4)
Gender: male (%) 36 (33.6)
Marital status: actual partner (%) 21 (19.6)
Residence: independent (%) 73 (68.2)
Dependent (%) 25 (23.4)
Hospitalized (%) 9 (8.4)
Educationa: low (%) 29 (27.4)
Middle (%) 44 (41.5)
High (%) 33 (31.1)
Diagnosis: schizophrenia (%) 84 (78.5)
Schizoaffective disorder (%) 23 (21.5)
Age at onset: mean years (SD) 37.3 (16.5)
Early (b40 years) (%) 71 (66.4)
Late (40–60 years) (%) 25 (23.4)
Very late (≥60 years) (%) 11 (10.3)
Duration of illness: mean years (SD) 30.6 (14.5)
PANSS score: total (mean, SD) 58.5 (15.3)
Positive subscale (mean, SD) 13.8 (5.3)
Negative subscale (mean, SD) 16.0 (6.2)
Symptomatic remission (%) 31 (29.0)
CES-D scorea: mean (SD) 16.3 (11.8)
BAI score: median (25–75%) 7 (3–16)
MMSE score: median (25–75%) 28 (26–29)
Mean (SD) 26.8 (3.3)
Chronic physical disorders: median (25–75%) 1 (0–2)
Network size: small (0–1 person) (%) 30 (28.0)
Medium (2–5 persons) (%) 41 (38.3)
Large (≥6 persons) (%) 36 (33.6)
Conﬁdant/supportive person: none (%) 33 (30.8)
1 person (%) 33 (30.8)
≥2 persons (%) 41 (38.3)
Social Participation Scale score: mean (SD) 9.3 (4.3)
SOFAS score: mean (SD) 52.4 (13.2)
PANSS = Positive and Negative Syndrome Scale; CES-D = Center for Epidemiologic
Studies Depression scale; BAI = Beck Anxiety inventory; MMSE = Mini Mental State
Examination; SOFAS = Social and Occupational Functioning Assessment Scale.
a 1 case missing.
Table 2




Mean SD N %
Item
Life in general 4.53 1.60 58 54.2
Not having paid employment 4.93 1.65 72 67.3
Financial situation 4.85 1.66 69 64.5
Number and quality of friendships 4.72 1.53 62 57.9
Daily activities 4.78 1.37 66 61.7
Accommodation 5.03 1.67 73 68.2
Personal safety 5.10 1.39 76 71.0
Fellow residents (partner, others)c 4.94 1.55 66 61.7
Sex life 4.68 1.76 64 59.8
Relationship with family 4.86 1.67 65 60.7
Physical health 4.68 1.58 61 57.0
Mental health 4.83 1.50 72 67.3
Total score 4.83 0.96 51 47.7
a Scoring range: 1 (could not be worse) to 7 (could not be better).
b Mean score ≥5.
c Patients without fellow residents reported their satisfaction with living alone.
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tioning in the previous week. SOFAS scores may range from 1 to 100,
with scores ≥61 indicating little or no social impairments.
SQOL was evaluated with the Manchester Short Assessment of
Quality of Life (MANSA; Priebe et al., 1999). The MANSA is a brief and
modiﬁed version of thewell-established Lancashire Quality of Life Proﬁle
(Oliver et al., 1997), and is easily applicable in older patients. The instru-
ment applies a generic concept of quality of life, assessing patient satis-
faction with 12 aspects of life. Satisfaction is rated on 7-point rating
scales, ranging from 1 (‘could not be worse’) to 7 (‘could not be better’),
with 4 (‘alternately satisﬁed and dissatisﬁed’) as a midpoint. The total
MANSA score is the mean of the 12 individual item scores. The MANSA
was completed in an oral interview.
Interviews were conducted by a psychiatrist (the ﬁrst author) and
two experienced psychiatric residents (diagnostic interview, PANSS,
MMSE), and by three well-trained psychiatric nurses (other variables).
Training for the PANSS included investigator meetings both at the start
and during the study, with rating of videotaped interviews, followed by
discussion and review of ratings. The internal reliability of the MANSA
was good (Cronbach's alpha = 0.84). The Cronbach's alpha scores of
the other employed scales were: PANSS total scale (0.81), PANSS positive
scale (0.59), PANSS negative scale (0.75), CES-D (0.89), BAI (0.89), Social
Participation Scale (0.74), MMSE (0.64).
2.3. Statistical analysis
To examine the relationship between the independent variables and
SQOL, bivariate analyseswere performedwith the totalMANSA score as
the dependent variable. The explained variances accounted for by each
of the three domains (demographic, clinical, social) were calculated. In
multivariable analysis, we initially examined each domain, entering
those variables which had attained a signiﬁcance level of p b 0.10 in
bivariate analysis. In addition, age and MMSE-score were entered,
because of their theoretical importance in this elderly study population.
The BAI score was not included in the multivariable analysis, as it
was strongly correlated with the CES-D scale (Pearson's r = 0.72,
p b 0.001). The number of conﬁdants was also excluded, as it was highly
correlated with the network size (Pearson's r = 0.58, p b 0.001). Next,
all variables with p b 0.10 in the domain-speciﬁc analyses were entered
in the ﬁnal multivariable analysis. The dependent variable met assump-
tions of normality andhomogeneity of variance. Therewas no collinearity
among the independent variables. Data were analyzed using the Statis-
tical Package of the Social Sciences (SPSS), version 20.0.
3. Results
3.1. Patient characteristics
Characteristics of the study sample are presented in Table 1. The
mean age of the participants was 67.9 years (range 60–94 years),
two-thirds were women. A large majority (68.2%) lived independently,
while 23.4% was living in psychiatric residential care (21.5%), or in a
general residential facility (1.9%). 8.4% of the participants was hospital-
ized at the time of study. In one-third, the psychotic disorder developed
after the age of 40. PANSS scores indicated that on average participants
had comparatively mild levels of psychotic symptoms. MMSE scores
demonstrated that most participants had no clinically signiﬁcant global
cognitive impairment; however, 15.9% of all participants had a MMSE
score below 24. Of all participants 28% had either a very small or no
social network outside of their household. The mean SOFAS score
(52.4) corresponds to moderate difﬁculty in social functioning.
3.2. Subjective quality of life
Table 2 presents the single item scores on the MANSA, ranging
from 4.53 ± 1.60 (life in general) to 5.10 ± 1.39 (personal safety).The mean score of all MANSA items was 4.83 ± 0.96. Nearly half of
the patients (47.7%) reported an overall favorable quality of life
(mean MANSA score ≥5).
3.3. Predictors of subjective quality of life
Table 3 presents the results of the bivariate analyses. Within the
demographic domain, a statistical trend was found for gender, with
female gender being associated with a higher SQOL. Within the clinical
Table 3
Bivariate analysis of demographic, clinical and social variables, with subjective quality
of life as dependent variable (in bold, p-values b 0.10).
n β p
Demographic domain
Age 107 0.11 0.26
Female gender 107 0.19 0.052
Actual partner 107 −0.10 0.29
Residence (independent vs. hospitalized) 107 0.08 0.63
(dependent vs. hospitalized) 0.04 0.80
Education (high vs. low) 106 −0.06 0.60
(Medium vs. low) 0.07 0.55
Clinical domain
Age at onset 107 0.14 0.15
Duration of illness 107 −0.11 0.28
PANSS: positive subscale score 107 −0.20 0.04
Negative subscale score 107 −0.04 0.70
Symptomatic remission 107 0.10 0.30
CES-D score 106 −0.68 b0.001
BAI score 107 −0.48 b0.001
MMSE score 107 −0.06 0.55
Chronic physical disorders 107 −0.18 0.07
Social domain
Network size (large vs. small) 107 0.25 0.03
(Medium vs. small) 0.03 0.78
Conﬁdant/supportive person (≥2 persons vs none) 107 0.16 0.17
(1 person vs none) 0.28 0.01
Social Participation Scale score 107 0.22 0.02
SOFAS score 107 0.37 b0.001
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score and the number of chronic physical disorders were negatively
associated with SQOL. In the social domain, the network size (large vs.
small), the availability of a conﬁdant/supportive person (1 person vs.
none), the Social Participation Scale score and the SOFAS score were
positively associated with SQOL. Of the total variance in SQOL, clinical
predictors explained 50% (F = 12.8, df = 9, 105, p b 0.001), while
social predictors explained 16% (F = 4.41, df = 6, 106, p = 0.001).
Demographic predictors did not signiﬁcantly contribute to SQOL vari-
ance (F = 1.04, df = 7, 105, p = 0.41).
Inmultivariable analysis (Table 4), three variableswithin the clinical
domain (PANSS positive score, CES-D score, MMSE score) signiﬁcantly
predicted SQOL.Within the social domain, only the SOFAS scorewas pre-
dictive of SQOL. In the ﬁnal multivariable analysis (entering gender,
PANSS positive subscale score, CES-D score, MMSE score, and SOFAS
score), the CES-D score (β = −0.62, p b 0.001), the MMSE score
(β = −0.22, p = 0.002), and the SOFAS score (β = 0.23, p = 0.003)
remained predictive of SQOL. This ﬁnal model explained 53% of the
total variance in SQOL (F = 24.8, df = 5, 105, p b 0.001).Table 4
Linear regression analysis of demographic, clinical and social variables predicting subjective




β df p β df p
Demographic domain
Age 0.07 106 0.52
Female gender 0.17 106 0.09 0.03 105 0.66
Clinical domain
PANSS: positive subscale score −0.17 105 0.02 −0.11 105 0.15
CES-D score −0.69 105 b0.001 −0.62 105 b0.001
MMSE score −0.18 105 0.01 −0.22 105 0.002
Chronic physical disorders 0.05 105 0.50
Social domain
Network size (large vs. small) −0.02 106 0.89
(Medium vs. small) −0.16 106 0.20
Social Participation Scale score 0.12 106 0.24
SOFAS score 0.35 106 0.002 0.23 105 0.0034. Discussion
4.1. Subjective quality of life
In this epidemiological cohort of elderly patients with schizophrenia
or schizoaffective disorder, the mean SQOL score was 4.83, moderately
surpassing the midpoint of the 1–7 scale. Nearly half of all participants
(47.7%) reported to experience a global favorable SQOL. The variation
between the individual SQOL-domains was only modest. The high
level of SQOL is notable, but compares well to what Bankole et al.
(2007) reported in their convenience sample of older community-
living patients in New York City. Relatively high levels of SQOL have
also been found in younger schizophrenia patients (Katschnig, 2000).
In addition, patients with schizophrenia generally rate their SQOL as
more favorable than those with mood and neurotic disorders, while in
all three disorders a positive association between age and SQOL has
been demonstrated (Priebe et al., 2010).SQOL relates to the gap between the aspirations of an individual and
his/her perceived reality. Comparisons with one's original ambitions, as
well as comparisons with the life situation and achievements of others,
inﬂuence appraisal of SQOL. Internal standards of comparison are
subject to change over time, as patients adjust to their disorder and its
consequences (Franz et al., 2000). As a result, while living in conditions
thatmay seem adversarial and unpleasant to others, patients can never-
theless be relatively satisﬁed with their life. This is reﬂected by the low
correlations between SQOL and objective indicators of quality of life in
schizophrenia (Priebe, 2007). In elderly populations, a survivor bias
may also come into play, as it iswell conceivable that higher functioning
patients stand a better chance to survive into old age. A longitudinal
study design would be needed to further clarify the relation between
aging and SQOL in schizophrenia.
4.2. Predictors of subjective quality of life
In bivariate analysis, nine of the 18 variables predicted SQOL signif-
icantly (p b 0.05). In the clinical domain, having less positive, depres-
sive or anxiety symptoms related to a higher SQOL. In the social
domain, a larger network size, presence of a conﬁdant person, greater
social participation, and higher level of social functioningwere associated
with a higher SQOL. In the ﬁnal multivariable analysis, having less
depressive symptoms and better social functioning were the remaining
predictors of a higher SQOL. In addition, a signiﬁcant effect of global
neurocognition was found in the multivariable analysis, with worse
cognitive functioning predicting a higher SQOL.
Mood symptoms accounted for a large amount of SQOL variance
(38%). Levels of self-reported depressive symptoms in our sample
were relatively high, with 46.2% of the patients scoring above the
threshold for clinically relevant depression in the general population
(CES-D score ≥16). In contrast, individual participants with higher
CES-D scores generally did not fulﬁl the DSM-IV criteria for major
depression, a ﬁnding which has been reported before in elderly
schizophrenia patients (Jin et al., 2001). Bankole et al. (2007) also found
that higher self-reported depression was associated with a lower SQOL,
although depressive symptoms explained less variance in their study
than in ours. The same holds true for younger schizophrenia patients,
forwhom the inﬂuence of depressive symptomsonSQOLhas consistently
been demonstrated, but with smaller impact than in our study (Eack and
Newhill, 2007).
The relationship between self-reported depressive symptoms and
SQOL needs to be evaluated cautiously. First, a potential bias may be
involved, as SQOL and self-reported depressive symptomsmay partially
reﬂect the same underlying affective state (Priebe, 2007). Next, while
depressive mood may lead to a lower SQOL, experiencing a lower
SQOL may in turn generate negative affective consequences. The
279P.D. Meesters et al. / Schizophrenia Research 147 (2013) 275–280cross-sectional design of our study prohibits further interpretation of
causality. However, evidence from prospective studies in younger
schizophrenia patients suggests that recovery of concurrent depression
leads to improvement of quality of life (Tollefson and Andersen, 1999;
Conley et al., 2007).
A predictive effect of global neurocognition on SQOL became apparent
only in the multivariable analysis, demonstrating that this effect implied
interaction with other variables. In separate analysis (data not shown),
we found that this mainly involved the level of depressive symptoms,
with participants with both low MMSE and CES-D scores reporting a
relatively high SQOL.
With a more modest magnitude, higher observer-based levels of
social functioning also predicted a higher SQOL. Social functioning is
a multifaceted phenomenon with a variety of interacting factors
(e.g., social support, coping style), implicating a complex relationship
between social functioning and SQOL. In younger schizophrenia patients,
the contribution of social variables to SQOL has been demonstrated
(Yanos and Moos, 2007), and psychosocial treatment strategies have
reported clear improvements in SQOL (Björkman and Hansson, 2007).
In contrast, in late life schizophrenia this area has received little attention
(Bartels and Pratt, 2009).
4.3. Strengths and limitations
The clinical relevance of our ﬁndings is strengthened by the epidemi-
ological design of the study, as we aimed to recruit all treated patients
within a psychiatric catchment area. We included community-living as
well as institutionalized patients, and set no restrictions to the age at
onset of their disorder. However, our ﬁndings only concern patients
who were able and willing to consent to participate in this research.
Speciﬁcally the view of patients with higher symptom levels may
have beenmissed in this respect. The administration of the SQOL instru-
ment in an oral interviewmay have prompted some participants to an-
swer questions in a socially desirable manner. However, we preferred
this method to enhance the reliability of self-report, given the frailty
of the population under study. Another limitation of the present study
was the use of multiple comparisons, which increased the probability
of type 1 errors. However, when the chance of incorrectly producing a
difference on an individual test (a type 1 error) is reduced, the chance
of making a type 2 error is increased, which implies that no effect
or difference is declared, while in fact there is an effect. Therefore,
we have not made the Bonferroni correction.
We consider the fact that our ﬁnal model explained 53% of variance
in SQOL as an indication of the robustness of thismodel. Nevertheless, it
also indicates that other factors relating to SQOL have major relevance.
Personal coping styles (Cohen et al., 2011) and stigmatization (Depla
et al., 2005) are examples of other potentially relevant variables. In a
previous publication on this cohort, we reported a substantial correla-
tion between SQOL and the number of unmet needs for care as per-
ceived by the patients (Meesters et al., 2013). However, in the present
study we did not include unmet needs as a predictor, as the extensive
overlap of the domains measured in SQOL and in the assessment of
needs substantially impairs the discriminant validity of these two con-
cepts (Reininghaus and Priebe, 2012).
4.4. Conclusion
Our study indicates that in late life schizophrenia depressed mood
and social functioning are among the relevant predictors of SQOL.
Depressive symptoms appear to be amore important source of distress
than psychotic symptoms, on which treatment traditionally tends to
focus. Pharmacological and/or psychosocial treatments for syndromal
as well as subsyndromal depression may prove fruitful for improving
SQOL among this population (Kasckow et al., 2010). Next, an emerging
body of literature suggests that various forms of psychosocial reha-
bilitation offer promising starting points for targeting SQOL in elderlyschizophrenia patients (Bartels and Pratt, 2009). Regarding future
research, qualitative study methods can offer a more sophisticated
approach to further explore SQOL and its determinants (Shepherd et al.,
2012).
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